Related Experiment Video
Updated: Mar 15, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications
Nicolaj C Hansson1, Erik L Grove2, Henning R Andersen1
1Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Insights
Transcatheter heart valve (THV) thrombosis occurred in 7% of patients post-transcatheter aortic valve replacement (TAVR). Larger THV size increased risk, while warfarin treatment showed a protective effect against THV thrombosis.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Imaging
Background:
- Limited data exists on transcatheter heart valve (THV) thrombosis post-transcatheter aortic valve replacement (TAVR).
- Understanding incidence, clinical impact, and risk factors for THV thrombosis is crucial.
Purpose of the Study:
- To assess the incidence of THV thrombosis after TAVR.
- To identify predictors and clinical implications of THV thrombosis.
- To evaluate the effectiveness of warfarin in managing THV thrombosis.
Main Methods:
- Contrast-enhanced multidetector computed tomography (MDCT) was used to evaluate 405 patients post-TAVR.
- MDCT scans were analyzed for hypoattenuated leaflet thickening, indicating THV thrombosis.
- Follow-up imaging assessed the impact of warfarin treatment.
Main Results:
- THV thrombosis was detected in 7% of patients (28/405).
- Larger THV size (29-mm) and absence of warfarin treatment were independent predictors of THV thrombosis.
- Warfarin treatment was associated with a significantly lower risk of THV thrombosis (1.8% vs. 10.7%).
Conclusions:
- THV thrombosis occurs in 7% of patients post-TAVR, often subclinically.
- Larger THV size is a risk factor, while warfarin may be protective.
- THV thrombosis has significant clinical implications, but warfarin treatment can effectively reverse it.
Background:
There are limited data on the incidence, clinical implications, and predisposing factors of transcatheter heart valve (THV) thrombosis following transcatheter aortic valve replacement (TAVR).
Objectives:
The authors assessed the incidence, potential predictors, and clinical implications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR.
Methods:
Among 460 consecutive patients who underwent TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) THV, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1 to 3 months post-TAVR. MDCT scans were evaluated for hypoattenuated leaflet thickening that indicated THV thrombosis.
Results:
MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, whereas 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ among different generations of THVs (8% vs. 6%; p = 0.42). The risk of THV thrombosis in patients who did not receive warfarin was higher compared with patients who received warfarin (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). A larger THV was associated with an increased risk of THV thrombosis (p = 0.03). In multivariable analysis, a 29-mm THV (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT.
Conclusions:
Incidence of THV thrombosis in this large study was 7%. A larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications.
More Related Videos
06:59Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care